The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update
Obesity is the fifth leading risk factor for global deaths with numbers continuing to increase worldwide. In the last 20 years, the emergence of pharmacological treatments for obesity based on gastrointestinal hormones has transformed the therapeutic landscape. The successful development of glucagon...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Endocrine Society
2024-02-01
|
| Series: | Endocrinology and Metabolism |
| Subjects: | |
| Online Access: | http://www.e-enm.org/upload/pdf/enm-2024-1942.pdf |
| _version_ | 1827339078102679552 |
|---|---|
| author | Agnieszka Jakubowska Carel W. le Roux Adie Viljoen |
| author_facet | Agnieszka Jakubowska Carel W. le Roux Adie Viljoen |
| author_sort | Agnieszka Jakubowska |
| collection | DOAJ |
| description | Obesity is the fifth leading risk factor for global deaths with numbers continuing to increase worldwide. In the last 20 years, the emergence of pharmacological treatments for obesity based on gastrointestinal hormones has transformed the therapeutic landscape. The successful development of glucagon-like peptide-1 (GLP-1) receptor agonists, followed by the synergistic combined effect of glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists achieved remarkable weight loss and glycemic control in those with the diseases of obesity and type 2 diabetes. The multiple cardiometabolic benefits include improving glycemic control, lipid profiles, blood pressure, inflammation, and hepatic steatosis. The 2023 phase 2 double-blind, randomized controlled trial evaluating a GLP-1/GIP/glucagon receptor triagonist (retatrutide) in patients with the disease of obesity reported 24.2% weight loss at 48 weeks with 12 mg retatrutide. This review evaluates the current available evidence for GLP-1 receptor agonists, dual GLP-1/GIP receptor co-agonists with a focus on GLP-1/GIP/glucagon receptor triagonists and discusses the potential future benefits and research directions. |
| first_indexed | 2024-03-07T19:45:53Z |
| format | Article |
| id | doaj.art-dab28375e9b14a58bd023c9cd65ea6a7 |
| institution | Directory Open Access Journal |
| issn | 2093-596X 2093-5978 |
| language | English |
| last_indexed | 2024-03-07T19:45:53Z |
| publishDate | 2024-02-01 |
| publisher | Korean Endocrine Society |
| record_format | Article |
| series | Endocrinology and Metabolism |
| spelling | doaj.art-dab28375e9b14a58bd023c9cd65ea6a72024-02-29T00:43:22ZengKorean Endocrine SocietyEndocrinology and Metabolism2093-596X2093-59782024-02-01391122210.3803/EnM.2024.19422465The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An UpdateAgnieszka Jakubowska0Carel W. le Roux1Adie Viljoen2 Borthwick Diabetes Research Centre, Lister Hospital, Stevenage, UK Diabetes Complications Research Centre, University College Dublin, Dublin, Ireland Borthwick Diabetes Research Centre, Lister Hospital, Stevenage, UKObesity is the fifth leading risk factor for global deaths with numbers continuing to increase worldwide. In the last 20 years, the emergence of pharmacological treatments for obesity based on gastrointestinal hormones has transformed the therapeutic landscape. The successful development of glucagon-like peptide-1 (GLP-1) receptor agonists, followed by the synergistic combined effect of glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists achieved remarkable weight loss and glycemic control in those with the diseases of obesity and type 2 diabetes. The multiple cardiometabolic benefits include improving glycemic control, lipid profiles, blood pressure, inflammation, and hepatic steatosis. The 2023 phase 2 double-blind, randomized controlled trial evaluating a GLP-1/GIP/glucagon receptor triagonist (retatrutide) in patients with the disease of obesity reported 24.2% weight loss at 48 weeks with 12 mg retatrutide. This review evaluates the current available evidence for GLP-1 receptor agonists, dual GLP-1/GIP receptor co-agonists with a focus on GLP-1/GIP/glucagon receptor triagonists and discusses the potential future benefits and research directions.http://www.e-enm.org/upload/pdf/enm-2024-1942.pdftriple agoniststriagonistsglucagon-like peptide 1gastric inhibitory polypeptideglucagonobesityweight lossretatrutideco-agonist |
| spellingShingle | Agnieszka Jakubowska Carel W. le Roux Adie Viljoen The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update Endocrinology and Metabolism triple agonists triagonists glucagon-like peptide 1 gastric inhibitory polypeptide glucagon obesity weight loss retatrutide co-agonist |
| title | The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update |
| title_full | The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update |
| title_fullStr | The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update |
| title_full_unstemmed | The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update |
| title_short | The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update |
| title_sort | road towards triple agonists glucagon like peptide 1 glucose dependent insulinotropic polypeptide and glucagon receptor an update |
| topic | triple agonists triagonists glucagon-like peptide 1 gastric inhibitory polypeptide glucagon obesity weight loss retatrutide co-agonist |
| url | http://www.e-enm.org/upload/pdf/enm-2024-1942.pdf |
| work_keys_str_mv | AT agnieszkajakubowska theroadtowardstripleagonistsglucagonlikepeptide1glucosedependentinsulinotropicpolypeptideandglucagonreceptoranupdate AT carelwleroux theroadtowardstripleagonistsglucagonlikepeptide1glucosedependentinsulinotropicpolypeptideandglucagonreceptoranupdate AT adieviljoen theroadtowardstripleagonistsglucagonlikepeptide1glucosedependentinsulinotropicpolypeptideandglucagonreceptoranupdate AT agnieszkajakubowska roadtowardstripleagonistsglucagonlikepeptide1glucosedependentinsulinotropicpolypeptideandglucagonreceptoranupdate AT carelwleroux roadtowardstripleagonistsglucagonlikepeptide1glucosedependentinsulinotropicpolypeptideandglucagonreceptoranupdate AT adieviljoen roadtowardstripleagonistsglucagonlikepeptide1glucosedependentinsulinotropicpolypeptideandglucagonreceptoranupdate |